01—Abstract
Summary
Summary of the 8-K filed March 17, 2026. Cited figures are marked; the original filing is the authoritative source.
Colgate-Palmolive filed an 8-K under Item 8.01 to disclose a realignment of its reportable operating segments, effective for the quarter ending March 31, 2026, as part of its previously announced Strategic Growth and Productivity Program.
The Europe and Africa/Eurasia segments (excluding Russia and Belarus) and the Skin Health business, previously in North America, will combine into a new Europe, Middle East & Africa (EMEA) segment. Russia and Belarus move into Asia Pacific. The company states this is a presentation change with no effect on historical consolidated results, financial position, or cash flows, and that the recast figures are not a restatement.
Exhibit 99 provides unaudited recast segment data for FY2023 through FY2025 and for the 2025 quarterly periods. On the recast basis, FY2025 net sales were $20.38 billiona, up about 1.4% from $20.10 billion in FY2024. Consolidated operating profit fell about 23% to $3.31 billion from $4.27 billion, driven mainly by Corporate expense, which rose to a $1.72 billion charge from $784 million.
Within the segments, EMEA was the standout, with operating profit up about 15% to $938 millionb, and Pet Nutrition rose about 10% to $1.06 billion. North America, Latin America, and Asia Pacific operating profit each declined roughly 8%. For investors, the key takeaways are that the new EMEA structure gives a clearer view of the Strategic Growth and Productivity Program's European effects, and that the recast data shows the 2025 profit decline sits largely in Corporate costs rather than in segment-level operations.
The filing does not explain the Corporate charge, so the drivers should be confirmed in the 10-K and subsequent earnings materials. Figures in the exhibit are unaudited and should be read alongside the FY2025 Form 10-K.
02—Key points
Key Highlights
- Segment realignment effective Q1 2026: Europe, Africa/Eurasia (ex-Russia/Belarus), and Skin Health combine into a new EMEA segment; Russia and Belarus move to Asia Pacific.
- The company states the realignment and recast have no impact on historical consolidated results, financial position, or cash flows, and do not constitute a restatement.
- FY2025 recast net sales of $20.38B, up ~1.4% vs. $20.10B in FY2024.
- FY2025 consolidated operating profit of $3.31B, down ~23% vs. $4.27B in FY2024, largely due to Corporate expense rising to $1.72B from $784M.
- EMEA operating profit rose ~15% to $938M in FY2025, while Pet Nutrition operating profit rose ~10% to $1.06B.
- North America, Latin America, and Asia Pacific segment operating profit each fell roughly 8% year over year in FY2025.
- Implied Q4 2025 Corporate charge of roughly $1.19B (FY2025 less nine-month figures), far above the $523M for the first nine months, suggests a concentrated fourth-quarter charge; the filing does not explain it.
03—Questions
Frequently Asked Questions
Does this segment realignment change Colgate's reported financial results?
No. The company states that the realignment and supplemental disclosures have no impact on historical consolidated results of operations, financial position, or cash flows. The recast segment information in Exhibit 99 is not a restatement of previously issued financial statements. Segment figures are unaudited and should be read with the FY2025 Form 10-K.
Why did the company move Russia and Belarus into Asia Pacific?
The filing ties the realignment to the Strategic Growth and Productivity Program, aimed at optimizing operating scale and driving growth in Europe and Africa/Eurasia. It does not give a detailed rationale for placing Russia and Belarus in Asia Pacific. Investors may want to check later management commentary for how these markets are now managed and reported.
What does the recast data show about profitability by segment in 2025?
EMEA was the strongest performer on the new basis, with FY2025 operating profit of $938M, up about 15% from $814M. Pet Nutrition rose about 10% to $1.06B. North America ($790M), Latin America ($1.41B), and Asia Pacific ($820M) each declined around 8%. Consolidated operating profit fell to $3.31B because Corporate expense increased sharply to $1.72B.
What drove the increase in Corporate expense in 2025?
The filing does not say. Corporate expense rose to $1,717M in 2025 from $784M in 2024, and the implied fourth-quarter charge is about $1.19B. This timing and size suggest a discrete item, possibly related to the Strategic Growth and Productivity Program, but that is not confirmed here. The FY2025 10-K and earnings materials should explain the drivers.
How did capital spending and D&A trend in 2025?
Total capital expenditures were $564M in 2025, roughly flat with $561M in 2024 and well below $705M in 2023. Depreciation and amortization rose to $630M from $605M, a 4% increase. Pet Nutrition capex fell sharply to $88M from $143M in 2024, while Latin America and Asia Pacific capex increased.
04—Continue